Latest Articles

Publication Date
IDEAYA Launches Breakthrough Phase 1 Trial: Novel PARG Inhibitor + KEYTRUDA for Endometrial Cancer - StockTitan

IDEAYA Launches Breakthrough Phase 1 Trial: Novel PARG Inhibitor + KEYTRUDA for Endometrial Cancer StockTitan

Published: Dec. 10, 2024, 11 a.m.
Butyrate as a Potential Modulator in Gynecological Disease Progression.

This review investigates the therapeutic potential of butyrate, a short-chain fatty acid (SCFA) produced by gut microbiota, in the prevention and treatment of various gynecological diseases, including polycystic ovary syndrome …

Published: Dec. 4, 2024, midnight
Endostatin-expressing endometrial mesenchymal stem cells inhibit angiogenesis in endometriosis through the miRNA-21-5p/TIMP3/PI3K/Akt/mTOR pathway.

Endometriosis is a chronic inflammatory and neoangiogenic disease. Endostatin is one of the most effective inhibitors of angiogenesis. Mesenchymal stem cells (MSCs) have been investigated as compelling options for cell …

Published: Nov. 26, 2024, midnight
Successful Treatment of Abdominal Wall Advanced Endometriosis-Associated Clear Cell Carcinoma with AKT Pathway Inhibitor: Case Report.

The emergence of endometriosis-associated clear cell carcinoma (CCC) within the abdominal wall is a notably rare phenomenon. This condition predominantly impacts females who have previously undergone surgical interventions, including hysterectomy …

Published: Nov. 26, 2024, midnight
mTOR inhibitors as potential therapeutics for endometriosis: A narrative review.

Mammalian target of rapamycin (mTOR) inhibitors have been used clinically as anticancer and immunosuppressive agents for over 20 years, demonstrating their safety after long-term administration. These inhibitors exhibit various effects, …

Published: Nov. 23, 2024, midnight
Comparative Analysis of Medical Interventions to Alleviate Endometriosis-Related Pain: A Systematic Review and Network Meta-Analysis.

Background/Objectives: Endometriosis is a chronic condition that affects 6-10% of women of reproductive age, with pain and infertility being its primary symptoms. The most common aspects of pain are overall …

Published: Nov. 18, 2024, midnight
Recent advances in the development of 17beta-hydroxysteroid dehydrogenase inhibitors.

The family of 17β-hydroxysteroid dehydrogenases (17β-HSDs) occupies a prominent place due to its number of isoforms, which carry out a bidirectional transformation (reduction of a steroid carbonyl to alcohol and …

Published: Nov. 10, 2024, midnight
[Exploring non-hormonal therapies and drug repositioning for endometriosis: insights from mouse model studies].

The mainstay of treatment for endometriosis is hormonal therapy, which suppresses ovulation; therefore, patients cannot conceive during treatment. There is a dilemma with ovarian-sparing surgery, known as laparoscopic cystectomy, as …

Published: Nov. 6, 2024, midnight
[Current and future medical treatment for endometriosis].

Endometriosis is a chronic, progressive inflammatory disease that occurs in approximately 10% of women of reproductive age, resulting in a decreased quality of life due to dysmenorrhea, chronic pain, and …

Published: Nov. 6, 2024, midnight
Targeting TET3 in macrophages provides a concept strategy for the treatment of endometriosis.

Endometriosis, characterized by the presence of endometrial-like tissue outside the uterus, is a condition associated with pain and infertility. In this issue of the JCI, Lv et al. illuminate the …

Published: Nov. 1, 2024, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!